Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study
Purpose: Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers. Materials and Methods: All patients consecutively diagnosed...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2022-12, Vol.18 (9), p.160-164 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 164 |
|---|---|
| container_issue | 9 |
| container_start_page | 160 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 18 |
| creator | Paleiron, Nicolas Gervais, Radj Rousseau-Bussac, Gaelle Game, Laurence Chiappa, Anne Lamy, Regine Guisier, Florian Le Caer, Hervé Robinet, Gilles Bizieux, Acya Chouaïd, Christos GFPC |
| description | Purpose: Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers.
Materials and Methods: All patients consecutively diagnosed with synchronous HNC and LC in 26 French centers were included. Information was collected on patients' clinical characteristics, management, and outcomes. Those characteristics and treatments were analyzed descriptively. Kaplan-Meier progression-free and overall survival probabilities were estimated.
Results: The study included 132 patients: 83% male; median age: 63.7 (range: 62.1-65.4) years; all current or former smokers; Eastern Cooperative Oncology Group performance status: 0 or 1 for 21.9% or 65.9% of the patients, respectively; cardiovascular comorbidities: 63%; chronic obstructive pulmonary disease: 33%; and previous cancer: 11%. HNC histology was 98% squamous: 23.5% oral cavity, 26.5% oropharyngeal, 22.0% hypopharyngeal, and 28.0% laryngeal. LCs were mainly localized (47.7% Stage I and 9.9% Stage II): 38% squamous, 49% adenocarcinomas, and 13% others. LC diagnosis impacted HNC management for 38% of the patients, with a median time from HNC diagnosis to first HNC treatment of 40 days. HNC impacted LC management for 48% of the patients, with a median time from LC diagnosis-to-LC treatment interval of 41 days.
Conclusions: Synchronous LC at HNC diagnosis impacted management and outcomes of both cancers. Specific recommendations should be elaborated to improve the management of these patients. |
| doi_str_mv | 10.4103/jcrt.JCRT_784_20 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04175002v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A729944641</galeid><sourcerecordid>A729944641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525e-c94c1fadb05ea2bba5755e52307ffc0322790b5091af2acea3390d38d506fe403</originalsourceid><addsrcrecordid>eNp1ks1vEzEQxVcIRNPCnROyxAUOG8Zf8ZpbGtEGFFpUyoGT5Xi9ySYbO9i7jfLf41Xa8qEgHzwa_d6Mnv2y7BWGIcNA369MaIefJze3ShRMEXiSDbCURc4wLZ5mA5CC5pgV5CQ7jXEFwAUhxfPshI44BsmLQaa_aKcXdmNdi3yFtrqtUxnRrm6XKO6dWQbvfBfR0uoy167MnTVrlArUdG6BjHbGhvgBfftxNZneXF-hy4uvE4R5DhjFtiv3L7JnlW6ifXl_n2XfLz7eTqb57Pry02Q8yw0n3OZGMoMrXc6BW03mc80F55YTCqKqDFBChIQ5B4l1RbSxmlIJJS1KDqPKMqBn2bvD3KVu1DbUGx32yutaTccz1feAYcEByB1O7NsDuw3-Z2djqzZ1NLZptLPJrCKCM2BSCJ7QN_-gK98Fl5z0FJVihDH5TS10Y1XtKt8GbfqhaiyIlIyNWL82P0ItrLNBN97Zqk7tv_jhET6d0m5qc1QAB4EJPsZgq8eHwKD6xKg-MeqPxCTJ63t_3Xxjy0fBQ0QScH4Adr5p01evm25ng0rs2vndfwcrPAL1EC76Cz6Wz2Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2753976112</pqid></control><display><type>article</type><title>Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Paleiron, Nicolas ; Gervais, Radj ; Rousseau-Bussac, Gaelle ; Game, Laurence ; Chiappa, Anne ; Lamy, Regine ; Guisier, Florian ; Le Caer, Hervé ; Robinet, Gilles ; Bizieux, Acya ; Chouaïd, Christos ; GFPC</creator><creatorcontrib>Paleiron, Nicolas ; Gervais, Radj ; Rousseau-Bussac, Gaelle ; Game, Laurence ; Chiappa, Anne ; Lamy, Regine ; Guisier, Florian ; Le Caer, Hervé ; Robinet, Gilles ; Bizieux, Acya ; Chouaïd, Christos ; GFPC ; GFPC</creatorcontrib><description>Purpose: Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers.
Materials and Methods: All patients consecutively diagnosed with synchronous HNC and LC in 26 French centers were included. Information was collected on patients' clinical characteristics, management, and outcomes. Those characteristics and treatments were analyzed descriptively. Kaplan-Meier progression-free and overall survival probabilities were estimated.
Results: The study included 132 patients: 83% male; median age: 63.7 (range: 62.1-65.4) years; all current or former smokers; Eastern Cooperative Oncology Group performance status: 0 or 1 for 21.9% or 65.9% of the patients, respectively; cardiovascular comorbidities: 63%; chronic obstructive pulmonary disease: 33%; and previous cancer: 11%. HNC histology was 98% squamous: 23.5% oral cavity, 26.5% oropharyngeal, 22.0% hypopharyngeal, and 28.0% laryngeal. LCs were mainly localized (47.7% Stage I and 9.9% Stage II): 38% squamous, 49% adenocarcinomas, and 13% others. LC diagnosis impacted HNC management for 38% of the patients, with a median time from HNC diagnosis to first HNC treatment of 40 days. HNC impacted LC management for 48% of the patients, with a median time from LC diagnosis-to-LC treatment interval of 41 days.
Conclusions: Synchronous LC at HNC diagnosis impacted management and outcomes of both cancers. Specific recommendations should be elaborated to improve the management of these patients.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.JCRT_784_20</identifier><identifier>PMID: 36510958</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Adenocarcinoma ; Carcinoma, Squamous Cell ; Carcinoma, Squamous Cell - epidemiology ; Carcinoma, Squamous Cell - therapy ; Care and treatment ; Diagnosis ; Esophageal cancer ; Female ; Head & neck cancer ; Head and neck cancer ; Head and Neck Neoplasms ; Head and Neck Neoplasms - diagnosis ; Head and Neck Neoplasms - epidemiology ; Head and Neck Neoplasms - therapy ; Humans ; Life Sciences ; Lung cancer ; Lung Neoplasms ; Lung Neoplasms - epidemiology ; Lung Neoplasms - therapy ; Male ; Meta-analysis ; Middle Aged ; Polymorphism</subject><ispartof>Journal of cancer research and therapeutics, 2022-12, Vol.18 (9), p.160-164</ispartof><rights>COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd.</rights><rights>2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525e-c94c1fadb05ea2bba5755e52307ffc0322790b5091af2acea3390d38d506fe403</citedby><cites>FETCH-LOGICAL-c525e-c94c1fadb05ea2bba5755e52307ffc0322790b5091af2acea3390d38d506fe403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27437,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36510958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://normandie-univ.hal.science/hal-04175002$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Paleiron, Nicolas</creatorcontrib><creatorcontrib>Gervais, Radj</creatorcontrib><creatorcontrib>Rousseau-Bussac, Gaelle</creatorcontrib><creatorcontrib>Game, Laurence</creatorcontrib><creatorcontrib>Chiappa, Anne</creatorcontrib><creatorcontrib>Lamy, Regine</creatorcontrib><creatorcontrib>Guisier, Florian</creatorcontrib><creatorcontrib>Le Caer, Hervé</creatorcontrib><creatorcontrib>Robinet, Gilles</creatorcontrib><creatorcontrib>Bizieux, Acya</creatorcontrib><creatorcontrib>Chouaïd, Christos</creatorcontrib><creatorcontrib>GFPC</creatorcontrib><creatorcontrib>GFPC</creatorcontrib><title>Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Purpose: Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers.
Materials and Methods: All patients consecutively diagnosed with synchronous HNC and LC in 26 French centers were included. Information was collected on patients' clinical characteristics, management, and outcomes. Those characteristics and treatments were analyzed descriptively. Kaplan-Meier progression-free and overall survival probabilities were estimated.
Results: The study included 132 patients: 83% male; median age: 63.7 (range: 62.1-65.4) years; all current or former smokers; Eastern Cooperative Oncology Group performance status: 0 or 1 for 21.9% or 65.9% of the patients, respectively; cardiovascular comorbidities: 63%; chronic obstructive pulmonary disease: 33%; and previous cancer: 11%. HNC histology was 98% squamous: 23.5% oral cavity, 26.5% oropharyngeal, 22.0% hypopharyngeal, and 28.0% laryngeal. LCs were mainly localized (47.7% Stage I and 9.9% Stage II): 38% squamous, 49% adenocarcinomas, and 13% others. LC diagnosis impacted HNC management for 38% of the patients, with a median time from HNC diagnosis to first HNC treatment of 40 days. HNC impacted LC management for 48% of the patients, with a median time from LC diagnosis-to-LC treatment interval of 41 days.
Conclusions: Synchronous LC at HNC diagnosis impacted management and outcomes of both cancers. Specific recommendations should be elaborated to improve the management of these patients.</description><subject>Adenocarcinoma</subject><subject>Carcinoma, Squamous Cell</subject><subject>Carcinoma, Squamous Cell - epidemiology</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Esophageal cancer</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>Head and neck cancer</subject><subject>Head and Neck Neoplasms</subject><subject>Head and Neck Neoplasms - diagnosis</subject><subject>Head and Neck Neoplasms - epidemiology</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Lung cancer</subject><subject>Lung Neoplasms</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Meta-analysis</subject><subject>Middle Aged</subject><subject>Polymorphism</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1ks1vEzEQxVcIRNPCnROyxAUOG8Zf8ZpbGtEGFFpUyoGT5Xi9ySYbO9i7jfLf41Xa8qEgHzwa_d6Mnv2y7BWGIcNA369MaIefJze3ShRMEXiSDbCURc4wLZ5mA5CC5pgV5CQ7jXEFwAUhxfPshI44BsmLQaa_aKcXdmNdi3yFtrqtUxnRrm6XKO6dWQbvfBfR0uoy167MnTVrlArUdG6BjHbGhvgBfftxNZneXF-hy4uvE4R5DhjFtiv3L7JnlW6ifXl_n2XfLz7eTqb57Pry02Q8yw0n3OZGMoMrXc6BW03mc80F55YTCqKqDFBChIQ5B4l1RbSxmlIJJS1KDqPKMqBn2bvD3KVu1DbUGx32yutaTccz1feAYcEByB1O7NsDuw3-Z2djqzZ1NLZptLPJrCKCM2BSCJ7QN_-gK98Fl5z0FJVihDH5TS10Y1XtKt8GbfqhaiyIlIyNWL82P0ItrLNBN97Zqk7tv_jhET6d0m5qc1QAB4EJPsZgq8eHwKD6xKg-MeqPxCTJ63t_3Xxjy0fBQ0QScH4Adr5p01evm25ng0rs2vndfwcrPAL1EC76Cz6Wz2Q</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Paleiron, Nicolas</creator><creator>Gervais, Radj</creator><creator>Rousseau-Bussac, Gaelle</creator><creator>Game, Laurence</creator><creator>Chiappa, Anne</creator><creator>Lamy, Regine</creator><creator>Guisier, Florian</creator><creator>Le Caer, Hervé</creator><creator>Robinet, Gilles</creator><creator>Bizieux, Acya</creator><creator>Chouaïd, Christos</creator><creator>GFPC</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Medknow Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20221201</creationdate><title>Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study</title><author>Paleiron, Nicolas ; Gervais, Radj ; Rousseau-Bussac, Gaelle ; Game, Laurence ; Chiappa, Anne ; Lamy, Regine ; Guisier, Florian ; Le Caer, Hervé ; Robinet, Gilles ; Bizieux, Acya ; Chouaïd, Christos ; GFPC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525e-c94c1fadb05ea2bba5755e52307ffc0322790b5091af2acea3390d38d506fe403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma</topic><topic>Carcinoma, Squamous Cell</topic><topic>Carcinoma, Squamous Cell - epidemiology</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Esophageal cancer</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>Head and neck cancer</topic><topic>Head and Neck Neoplasms</topic><topic>Head and Neck Neoplasms - diagnosis</topic><topic>Head and Neck Neoplasms - epidemiology</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Lung cancer</topic><topic>Lung Neoplasms</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Meta-analysis</topic><topic>Middle Aged</topic><topic>Polymorphism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paleiron, Nicolas</creatorcontrib><creatorcontrib>Gervais, Radj</creatorcontrib><creatorcontrib>Rousseau-Bussac, Gaelle</creatorcontrib><creatorcontrib>Game, Laurence</creatorcontrib><creatorcontrib>Chiappa, Anne</creatorcontrib><creatorcontrib>Lamy, Regine</creatorcontrib><creatorcontrib>Guisier, Florian</creatorcontrib><creatorcontrib>Le Caer, Hervé</creatorcontrib><creatorcontrib>Robinet, Gilles</creatorcontrib><creatorcontrib>Bizieux, Acya</creatorcontrib><creatorcontrib>Chouaïd, Christos</creatorcontrib><creatorcontrib>GFPC</creatorcontrib><creatorcontrib>GFPC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paleiron, Nicolas</au><au>Gervais, Radj</au><au>Rousseau-Bussac, Gaelle</au><au>Game, Laurence</au><au>Chiappa, Anne</au><au>Lamy, Regine</au><au>Guisier, Florian</au><au>Le Caer, Hervé</au><au>Robinet, Gilles</au><au>Bizieux, Acya</au><au>Chouaïd, Christos</au><au>GFPC</au><aucorp>GFPC</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>18</volume><issue>9</issue><spage>160</spage><epage>164</epage><pages>160-164</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Purpose: Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers.
Materials and Methods: All patients consecutively diagnosed with synchronous HNC and LC in 26 French centers were included. Information was collected on patients' clinical characteristics, management, and outcomes. Those characteristics and treatments were analyzed descriptively. Kaplan-Meier progression-free and overall survival probabilities were estimated.
Results: The study included 132 patients: 83% male; median age: 63.7 (range: 62.1-65.4) years; all current or former smokers; Eastern Cooperative Oncology Group performance status: 0 or 1 for 21.9% or 65.9% of the patients, respectively; cardiovascular comorbidities: 63%; chronic obstructive pulmonary disease: 33%; and previous cancer: 11%. HNC histology was 98% squamous: 23.5% oral cavity, 26.5% oropharyngeal, 22.0% hypopharyngeal, and 28.0% laryngeal. LCs were mainly localized (47.7% Stage I and 9.9% Stage II): 38% squamous, 49% adenocarcinomas, and 13% others. LC diagnosis impacted HNC management for 38% of the patients, with a median time from HNC diagnosis to first HNC treatment of 40 days. HNC impacted LC management for 48% of the patients, with a median time from LC diagnosis-to-LC treatment interval of 41 days.
Conclusions: Synchronous LC at HNC diagnosis impacted management and outcomes of both cancers. Specific recommendations should be elaborated to improve the management of these patients.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>36510958</pmid><doi>10.4103/jcrt.JCRT_784_20</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2022-12, Vol.18 (9), p.160-164 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04175002v1 |
| source | MEDLINE; Medknow Open Access Medical Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenocarcinoma Carcinoma, Squamous Cell Carcinoma, Squamous Cell - epidemiology Carcinoma, Squamous Cell - therapy Care and treatment Diagnosis Esophageal cancer Female Head & neck cancer Head and neck cancer Head and Neck Neoplasms Head and Neck Neoplasms - diagnosis Head and Neck Neoplasms - epidemiology Head and Neck Neoplasms - therapy Humans Life Sciences Lung cancer Lung Neoplasms Lung Neoplasms - epidemiology Lung Neoplasms - therapy Male Meta-analysis Middle Aged Polymorphism |
| title | Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T15%3A44%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20patients%20with%20synchronous%20head-and-neck%20and%20lung%20cancers:%20SYNCHRON%20GFPC%2015-01%20study&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Paleiron,%20Nicolas&rft.aucorp=GFPC&rft.date=2022-12-01&rft.volume=18&rft.issue=9&rft.spage=160&rft.epage=164&rft.pages=160-164&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.JCRT_784_20&rft_dat=%3Cgale_hal_p%3EA729944641%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2753976112&rft_id=info:pmid/36510958&rft_galeid=A729944641&rfr_iscdi=true |